M&A Deal Summary |
|
|---|---|
| Date | 2015-07-27 |
| Target | Caprelsa |
| Sector | Medical Products |
| Buyer(s) | Genzyme |
| Sellers(s) | AstraZeneca |
| Deal Type | Divestiture |
SEARCH BY
Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 12 of 12 |
| Sector: Medical Products M&A | 3 of 3 |
| Type: Divestiture M&A Deals | 2 of 2 |
| Country: United Kingdom M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-02-10 |
Genzyme Corp -Cholestagel
Ontario, Canada Genzyme Corp -Cholestagel(R) Colesevelam is a bile acid sequestrant administered orally. Cholestagel(R) is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. Cholestagel(R) is contraindicated in patients with bowel or biliary obstruction. Cholestagel(R) is contraindicated in patients with serum triglyceride (TG) > 500 mg/dL and in patients with a history of hypertiglyceridemia-induced pancreatitis. |
Sell | R$2M |
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Employees | 83,100 |
| Revenue | 54.1B USD (2024) |
AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 6 of 11 |
| Sector: Medical Products M&A | 3 of 3 |
| Type: Divestiture M&A Deals | 6 of 11 |
| Country: United Kingdom M&A | 1 of 5 |
| Year: 2015 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-11-06 |
Myalept
United States Myalept™ (metreleptin for injection) is an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy. |
Sell | $325M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-11-05 |
ZS Pharma
Coppell, Texas, United States ZS Pharma, founded in 2008, is a privately held specialty pharmaceutical company based in Coppell, Texas and Menlo Park, CA. Our core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. |
Buy | $2.7B |
